Here are three things to know:
1. The panel voted 10-to-two in favor of the safety of the implant for the treatment of osteoarthritis at the base of the great toe. It also voted nine to three in favor of the efficacy of the implant and eight-to-two, with two abstentions, that the benefits outweighed the risks.
2. The FDA is not bound by the panel’s recommendation, but will take it into consideration when reviewing Cartiva’s premarket approval application.
3. If approved, the Cartiva SCI will be the first synthetic cartilage device ever approved by the FDA.
More articles on devices:
SANUWAVE Health names A. Michael Stolarski to board: 4 quick facts
InVivo Therapeutics’ study subject dies; Neuro-Spinal Scaffold not the cause: 6 things to know
State of Tennessee Treasury Department buys 32k of NuVasive shares: 5 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
